More data requested on Vioxx successor
79247
Merck &amp; Co., which withdrew the Vioxx painkiller last month because of a heart risk, said yesterday that US regulators have asked for more safety data before they will approve the medicine&#39;s successor, Arcoxia.
198445
The global pharmaceutical industry  unveiled plans on Thursday to publish more data about trials of  medicines in a bid to reassure patients following recent alarms  over drug safety.
695199
Less than three months after Merck withdrew its pain-killer Vioxx from the US after concerns about side-effects, questions over Pfizer&#39;s competitor products are provoking
201667
WALL STREET analysts last night said a second experimental pain killer under development by Merck, the American drugs maker, could be delayed until 2007, after regulators asked for more information on the medicineâs safety.
266095
The pharmaceutical industry made a commitment Thursday to publish more data about clinical drug trials, amid growing questions about the safety of many leading companies' medicines.
49935
Description: A voluntary withdrawal of Vioxx from the market is the latest in a string of safety issues for the drug market. Dr. Alistair Wood, of the Vanderbilt School of Medicine, says the serious dangers
319964
The embattled pharmaceutical industry announced its intention Thursday to publish more data about clinical drug trials, despite skepticism about whether the initiative will really increase transparency and improve drug safety.
308413
Two years after the withdrawal of the painkiller Vioxx, federal health regulators still lack the resources necessary to track the safety of new drugs and respond quickly to any problems that might crop up, a panel of experts said Friday.
41856
Pfizer Inc.âs disclosure of a study linking Celebrex to heart attacks, such as Merck &amp; Co.âs withdrawn Vioxx, means demand for the drugs once known as âsuper aspirin
240261
Amid questions about whether the arthritis drug Vioxx was taken off the market soon enough, a key senator suggested Friday that an independent board of drug safety might be needed to ensure the safety of medications after they're approved for the market.
95097
NEW YORK -- The pharmaceutical industry yesterday said it plans to publish more data about clinical drug trials, despite skepticism about whether the initiative will increase transparency and improve drug safety.
476114
WASHINGTON - The FDA scientist who studied the safety of the recalled painkiller Vioxx delivered a bombshell Thursday, naming five more drugs he believes could be dangerous.
19213
Less than six weeks after Vioxx was pulled from pharmacy shelves because of evidence it increased a patient&#39;s risk of heart attack or stroke, some researchers are raising
145921
With the stunning recall of a popular pain medication last week and the impact it had on patients, the stock market and its manufacturer, it may be worthwhile to review how drugs get to market and how safety data are gathered.
253901
The public outcry over the withdrawal of the painkiller Vioxx is leading to closer government scrutiny of new drugs to identify and disclose late-developing safety problems.
506626
Merck pulled Vioxx from the market on September 30th, saying it was acting in the best interest of patients. But internal documents reportedly show the company knew as far back as 2000 that
332433
Merck&#39;s (MRK :NYSE - news - research) decision to withdraw its popular arthritis drug Vioxx from the market in late September has raised questions about the process leading up to its regulatory approval in 1999 as well as the importance of subsequent